Cormorant Asset Management

What Cormorant Asset Management does

Cormorant Asset Management, LP is a Boston-based, SEC-registered investment adviser founded in 2013 by Bihua Chen that focuses exclusively on public and private biotechnology and life sciences companies. The firm employs a long-term, fundamental, and research-intensive investment process grounded in deep scientific and therapeutic analysis of drugs, technologies, business models, and competitive landscape, with a stated goal of forming differentiated views relative to market consensus. Operations are run from a single headquarters at 200 Clarendon Street, 50th Floor, Boston, MA, with a lean team of approximately 11 professionals spanning investment, trading, analytics, IR, finance, and legal/compliance functions.

Cormorant generates revenue through traditional asset-management economics — management fees on assets under management and performance-based incentive fees on fund returns — and supplements this with a dedicated biotech SPAC franchise, of which Helix Acquisition Corp. III (Nasdaq: HLXC, $150M IPO in January 2026) is the most recent vehicle, intended to merge with a privately held healthcare target. Capital is distributed via direct institutional fundraising, SEC-registered public SPAC offerings, and participation in private placements, PIPEs, and registered direct offerings in biotech issuers, frequently alongside other specialist healthcare funds (RA Capital, OrbiMed, ARCH, Atlas Venture, Balyasny, Fidelity, Janus Henderson, Bain Capital, Eli Lilly, Sanofi). Implied AUM sits in the high hundreds of millions of dollars based on disclosed position sizing, with named recent activity spanning Adlai Nortye, Cabaletta Bio, Parabilis Medicines, nChroma Bio, Quince, Terremoto, Sensorion, MoonLake, and Rapport Therapeutics.

Name

Cormorant Asset Management

Legal name

Cormorant Asset Management, LP

Website

https://cormorant-asset.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Cormorant Asset Management is a Boston-based, SEC-registered investment adviser founded in 2013 by Bihua Chen that runs research-intensive public and private biotech portfolios and a biotech SPAC franchise. It serves institutional limited partners and biotech issuers, deploying capital alongside other specialist healthcare funds.

Ownership category

akta.pro rank

Product category

Biotechnology-focused Asset Management

NAICS

Portfolio Management and Investment Advice (523940), Investment Banking and Securities Intermediation (52315)

SIC

Investment Advice (6282)

akta.pro primary industry

LP-led Secondaries (Traditional LP Interest Purchases) (FSANAFAA)

Keywords

• Biotech asset management
• Healthcare hedge fund
• Life sciences investing
• Biotech SPAC vehicles
• Fundamental equity research

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Investment advisory / asset management fees: As an SEC-registered investment adviser managing public and private biotechnology and life sciences portfolios, Cormorant generates revenue through management fees on assets under management and performance-based incentive/carry fees on fund returns.
2. SPAC-related capital deployment and merger economics: Revenue generated from capital raised and deployed through dedicated SPAC vehicles (e.g., Helix Acquisition Corp. III IPO of $150M on Nasdaq under ticker HLXC), with economics tied to consummating a merger with a privately held healthcare or healthcare-related target.
3. Public equity long/short investing gains and losses: Realized and unrealized P&L from long positions in public biotech equities (e.g., realized exit in Arcellx worth $63.63M; MoonLake Immunotherapeutics stake; Rapport Therapeutics stake).

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

Cormorant Asset Management, LP is an SEC-registered investment adviser that manages public and private biotechnology and life sciences portfolios using a long-term, fundamental, research-intensive approach grounded in deep scientific and therapeutic analysis. In parallel, the firm operates a dedicated biotech SPAC franchise — most recently Helix Acquisition Corp. III (Nasdaq: HLXC) — designed to merge with privately held healthcare companies and provide an alternative path to public markets. Revenue is generated through investment advisory/asset management fees on its biotech funds and through SPAC-related capital deployment and merger economics.

Product overview

Cormorant Asset Management is a life sciences and healthcare focused investment firm offering a single core investment management service rather than a multi-product platform. Its primary offering is research-driven biotech investment management (public and private markets), built around a long-term, fundamental approach grounded in deep scientific and therapeutic analysis. Alongside the core investment service, the firm also operates Helix Acquisition Corp. III (HLXC), a Nasdaq-listed special purpose acquisition company (SPAC) launched to merge with a privately held healthcare or healthcare-related company. Together, these two offerings — the core biotech-focused investment management service and the Helix Acquisition Corp. III SPAC vehicle — comprise Cormorant's named product/service portfolio.

Differentiator

Problem solved

Functional benefit

Products and services

• Cormorant Biotech-Focused Investment Management Service SEC-registered investment advisory service that manages public and private biotechnology and life sciences portfolios using a long-term, fundamental, research-intensive approach grounded in deep scientific and therapeutic analysis; offered to institutional and qualified investors as a specialist biotech fund mandate.
• Helix Acquisition Corp. III (HLXC) Cormorant's third dedicated biotech special purpose acquisition company (SPAC), listed on Nasdaq under ticker HLXC, designed to identify and merge with a privately held healthcare or healthcare-related company as an alternative path to public markets.

Quantifiable outcome

• Co-led a $140M PIPE for Adlai Nortye at $2.1667/share (64,615,386 Class A ordinary shares)
• +10 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Helix Acquisition Corp. III (Cormorant's own SPAC)flagshipStrategic or Co-development Partner · 13 January 2026Cormorant's third dedicated biotech SPAC, Helix Acquisition Corp. III, raised $150M via an IPO of 15 million shares at $10 each, began trading on Nasdaq under ticker HLXC, and intends to merge with a privately held healthcare or healthcare-related company. A separate Institutional Investor source cites the IPO as closing at $172.5M; the firm has completed two prior successful SPAC deals since 2022.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• RA Capital Management: Boston-based, healthcare-focused crossover fund that invests across public and private biotech with deep scientific diligence. Directly comparable to Cormorant in sector focus, geography, and repeated co-investment alongside the same biotech issuers.
• Baker Bros. Advisors: Healthcare-focused, biotech-specialist long-only adviser co-founded by Felix and Julian Baker. Closely comparable to Cormorant in its public/private biotech focus and fundamental, science-driven underwriting approach.
• OrbiMed: Global healthcare-dedicated investment firm across venture, growth, debt, and public equity. Directly comparable to Cormorant as a sector-pure healthcare specialist co-investing in many of the same biotech rounds.
• EcoR1 Capital: Biotech-focused fund that invests in both public and private therapeutics companies with a fundamental, science-driven approach. Directly comparable to Cormorant in mandate, stage range, and biotech deal community presence.
• Perceptive Advisors: Healthcare and biotech-focused investment firm with crossover public/private strategies. Directly comparable to Cormorant in biotech focus and repeated co-investment alongside the same issuers (e.g., Adlai Nortye, Quince, Parabilis).
• Balyasny Asset Management: Multi-strategy hedge fund with a large dedicated healthcare franchise that co-leads biotech PIPEs and private rounds. Directly comparable to Cormorant as a co-leader in financings such as Quince Therapeutics and Adlai Nortye.
• ARCH Venture Partners: Biotech-focused venture firm investing from seed through public markets in life sciences companies. Directly comparable as a co-investor alongside Cormorant in deals like nChroma Bio, Terremoto, and Parabilis.
• Atlas Venture: Early-stage biotech-focused venture firm that builds and funds therapeutics companies. Comparable to Cormorant as a sector-pure biotech specialist and co-investor (e.g., nChroma Bio).

Broad incumbents

• Janus Henderson Investors: Large, diversified global asset manager with a significant healthcare franchise. Comparable to Cormorant as a co-investor in biotech financings (Quince, Parabilis), but operates at much broader scale and is not a specialist.
• Point72 Asset Management: Multi-strategy hedge fund with a dedicated healthcare and biotech team. Comparable as a co-investor in biotech PIPEs (e.g., Adlai Nortye) but operates across many strategies, not as a healthcare specialist.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cormorant-asset-management

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments287 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cormorant Asset Management